患者对性结肠炎先进疗法的偏好,使用联合分析
Taku Kobayashi1, Naomi Mizuno2, Noriko Sato2
1Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Intestinal research
|October 14, 2024
概括
患者对性结肠炎先进疗法的偏好差异很大. 服用途径/频率是关键,在轻微症状中偏好口服选择,而在严重病例中,发病速度至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 药物经济学 药物经济学
- 患者报告的结果
背景情况:
- 选择性结肠炎 (UC) 的最佳先进疗法是具有挑战性的,因为有许多治疗选择.
- 了解患者的偏好对于UC管理中有效的共享决策至关重要.
研究的目的:
- 评估患者对药物概况的偏好,以选择治疗性结肠炎 (UC) 的先进疗法.
- 根据疾病严重程度量化各种药物属性的重要性及其效用水平.
主要方法:
- 基于网络的联合分析调查对365名UC患者进行了调查.
- 评估的关键药物属性包括给药途径/频率,发病速度,可持续性,安全风险和新奇性.
- 在轻度和重度症状情景中分析了偏好,以及在就业患者和失业患者之间.
主要成果:
- 患者对UC先进疗法的偏好高度个性化.
- 服用途径/频率是轻度和重度UC情景中最重要的属性.
- 对于轻度症状,更喜欢口服;在严重症状情景中,更重视发病速度.
结论:
- 患者对UC先进疗法的偏好受疾病严重程度的影响,并表现出显著的个体间变异性.
- 共享决策对于在选择性结肠炎的先进疗法时整合患者观点至关重要.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126
Inflammatory Bowel Disease V: Surgical Management
126
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
126
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151


